Recommendations on nutrition and lifestyle for patients with non-alcoholic fatty liver disease


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Analysis of current data suggests that lifestyle modification and weight reduction are the first line of therapy of non-alcoholic fatty liver disease (NAFLD). For the treatment of NAFLD, it is recommended to reduce the caloric content of the diet (decrease by 500-1000 kcal per day in comparison with the usual regimen), to increase the number of products containing ω-3 polyunsaturated fatty acids (seafood) in the ration, and decrease the proportion of refined carbohydrates; systematic mid-intensity physical exercises and overall increase in physical activity, body weight reduction by 7-10% of the initial values in case of overweight are also recommended. The change in behavioral stereotypes that should contribute to the formation of a healthy lifestyle is of fundamental importance.

Full Text

Restricted Access

About the authors

V. V Tsukanov

Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North

Email: gastro@impn.ru
MD, Prof., Head of the Clinical Department of the Pathology of the Digestive System in Adults and Children FRC KSC SB RAS, SRI MPN

A. V Vasyutin

Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North

Yu. L Tonkikh

Federal Research Center “Krasnoyarsk Scientific Center" of the Siberian Branch of the Russian Academy of Sciences, Scientific Research Institute of Medical Problems of the North

References

  1. Younossi Z.M., Koenig A.B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
  2. Маев И.В., Цуканов В.В., Лукичева Э.В., Самсонов А.А., Васютин А.В., Никушкина И.Н. Распространенность, патогенез и принципы лечения неалкогольной жировой болезни печени. Фарматека. 2011;12:12-5.
  3. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23.
  4. Marchesini G., Day C.P., Dufour J.F., Canbay A., Nobili V., Ratziu V., Tilg H., Roden M., Gastaldelli A., Yki-Järvinen H., Schick F., Vettor R., Frühbeck G., Mathus-Vliegen L. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016;64(6):1388-402.
  5. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., Harrison S.A., Brunt E.M., Sanyal A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.
  6. Chitturi S., Wong V.W., Chan W.K., Wong G.L., Wong S.K., Sollano J., Ni Y.H., Liu C.J., Lin Y.C., Lesmana L.A., Kim S.U., Hashimoto E., Hamaguchi M., Goh K.L., Fan J., Duseja A., Dan Y.Y., Chawla Y., Farrell G., Chan H.L. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J. Gastroenterol. Hepatol. 2018;33(1):86-98.
  7. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О., Драпкина О.М., Шульпекова Ю.О., Цуканов В.В., Маммаев С.Н., Маев И.В., Пальгова Л.К. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2016;2:19-23.
  8. Zelber-Sagi S., Lotan R., Shlomai A., Webb M., Harrari G., Buch A., Nitzan Kaluski D., Halpern Z., Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J. Hepatol. 2012;56(5):1145-51.
  9. Koopman K.E., Caan M.W., Nederveen A.J., Pels A., Ackermans M.T, Fliers E., la Fleur S.E., Serlie M.J. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: a randomized controlled trial. Hepatology. 2014;60(2):545-53.
  10. Тонких Ю.Л., Цуканов В.В., Каспаров Э.В., Бронникова Е.П., Васютин А.В. Изменение соотношения насыщенных и ненасыщенных жирных кислот в крови - универсальный маркер нарушения липидного обмена у больных холелитиазом. Тер. архив. 2017;89(2):66-9.
  11. Цуканов В.В., Куперштейн Е.Ю., Тонких Ю.Л., Бронникова Е.П. Ассоциация жирнокислотного состава сыворотки крови с липидным составом желчи у больных холелитиазом. Тер. архив. 2008;80(2):71-5.
  12. Levy J.R., Clore J.N., Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004;39(3):608-16.
  13. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., Oren R. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J. Hepatol. 2007;47(5):711-17.
  14. Bjermo H., Iggman D., Kullberg J., Dahlman I., Johansson L., Persson L., Berglund J., Pulkki K., Basu S., Uusitupa M., Rudling M., Arner., Cederholm T., Ahlström H., Risérus U. Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial. Am. J. Clin. Nutr. 2012;95(5):1003-12.
  15. Parker H.M., Johnson N.A., Burdon C.A., Cohn J.S., O'Connor H.T., George J. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 2012;56(4):944-51.
  16. Argo C.K., Patrie J.T., Lackner C., Henry T.D., de Lange E.E., Weltman A.L., Shah N.L., Al-Osaimi A.M., Pramoonjago P., Jayakumar S., Binder L.P., Simmons-Egolf W.D., Burks S.G., Bao Y., Taylor A.G., Rodriguez J, Caldwell S.H. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 2015;62(1):190-97.
  17. Moriya A., Iwasaki Y., Ohguchi S., Kayashima E., Mitsumune T., Taniguchi H., Ando M., Yamamoto K. Roles of alcohol consumption in fatty liver: a longitudinal study. J Hepatol. 2015;62(4):921-27.
  18. Ascha M.S., Hanouneh I.A., Lopez R., Tamimi T.A., Feldstein A.F., Zein N.N. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6):1972-78.
  19. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., Johnson R.J., Abdelmalek M.F Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 2008;48(6):993-99.
  20. Ma J., Fox C.S., Jacques P.F., Speliotes E.K., Hoffmann U., Smith C.E., Saltzman E., McKeown N.M. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J. Hepatol. 2015;63(2):462-69.
  21. Fedirko V., Lukanova A., Bamia C., Trichopolou A., Trepo E., Nöthlings U. et al. Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk of liver and biliary tract cancers in Western Europeans. Ann. Oncol. 2013;24(2):543-53.
  22. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E,or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010;362(18):1675-85.
  23. Wei J., Lei G.H., Fu L., Zeng C., Yang T., Peng S.F. Association between Dietary Vitamin C Intake and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study among Middle-Aged and Older Adults. PLoS One. 2016;11(1):e0147985.
  24. Romero-Gomez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J. Hepatol. 2017;67(4):829-46.
  25. Grontved A., Hu F.B. Television viewing and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a meta-analysis. JAMA. 2011;305(23):2448-55
  26. Ryu S., Chang Y., Jung H.S., Yun K.E., Kwon M.J., Choi Y., Kim C.W., Cho J., Suh B.S., Cho Y.K., Chung E.C., Shin H., Kim Y.S. Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. J. Hepatol. 2015;63(5):1229-37
  27. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Zvibel I., Goldiner I., Blendis L., Halpern Z., Oren R. Role of leisure-time physical activity in nonalcoholic fatty liver disease: a population-based study. Hepatology. 2008;48(6):1791-98.
  28. Santaliestra-Pasias A.M., Mouratidou T., Huybrechts I., Beghin L., Cuenca-Garcfa M., Castillo M.J. et al. Increased sedentary behaviour is associated with unhealthy dietary patterns in European adolescents participating in the HELENA study. Eur. J. Clin. Nutr. 2014;68(3):300-8.
  29. Van der Windt D.J., Sud V., Zhang H., Tsung A., Huang H. The Effects of Physical Exercise on Fatty Liver Disease. Gene Expr. 2017. [Epub ahead of print].
  30. Hashida R., Kawaguchi T., Bekki M., Omoto M., Matsuse H., Nago T., Takano Y., Ueno T., Koga H., George J., Shiba N., Torimura T. Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review. J. Hepatol. 2017;66(1):142-52.
  31. Oh Y.S., Kim H.J., Ryu S.J., Cho K.A., Park Y.S., Park H., Kim M., Kim C.K., Park S.C. Exercise type and muscle fiber specific induction of caveolin-1 expression for insulin sensitivity of skeletal muscle. Exp. Mol. Med. 2007;39(3):395-401.
  32. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885-904.
  33. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., Fava J.L., Wing R.R. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121-29.
  34. Vilar-Gomez E., Yasells-Garcia A., Martinez-Perez Y., Calzadilla-Bertot L., Torres-Gonzalez A., Gra-Oramas B., Gonzalez-Fabian L., Villa-Jimenez O., Friedman S.L., Diago M., Romero-Gomez M. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology. 2016;63(6):1875-87.
  35. Jensen M.D., Ryan D.H., Apovian C.M., Ard J.D., Comuzzie A.G., Donato K.A., et al. 2013 AHA/ACC/ TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J. Am. Coll. Cardiol. 2014;63(25 Pt B): 2985-3023.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies